JP2023549703A5 - - Google Patents
Info
- Publication number
- JP2023549703A5 JP2023549703A5 JP2023526258A JP2023526258A JP2023549703A5 JP 2023549703 A5 JP2023549703 A5 JP 2023549703A5 JP 2023526258 A JP2023526258 A JP 2023526258A JP 2023526258 A JP2023526258 A JP 2023526258A JP 2023549703 A5 JP2023549703 A5 JP 2023549703A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- diabetes
- alkoxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107843P | 2020-10-30 | 2020-10-30 | |
| US63/107,843 | 2020-10-30 | ||
| PCT/IB2021/060045 WO2022091029A1 (en) | 2020-10-30 | 2021-10-29 | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549703A JP2023549703A (ja) | 2023-11-29 |
| JP2023549703A5 true JP2023549703A5 (https=) | 2024-10-31 |
Family
ID=81382016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526258A Pending JP2023549703A (ja) | 2020-10-30 | 2021-10-29 | ＢＥＴブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体２阻害剤の組み合わせを用いてＨｂＡ１ｃを低下させるための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230398137A1 (https=) |
| EP (1) | EP4236957A4 (https=) |
| JP (1) | JP2023549703A (https=) |
| TW (1) | TW202233195A (https=) |
| WO (1) | WO2022091029A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114650824A (zh) * | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060079121A (ko) * | 2004-12-31 | 2006-07-05 | 에스케이케미칼주식회사 | 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체 |
| JP2012528170A (ja) * | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| CA2851996C (en) * | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| US11419883B2 (en) * | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| RS65599B1 (sr) * | 2018-07-21 | 2024-06-28 | Linnaeus Therapeutics Inc | Enantiomerno prečišćeni gper agonist za upotrebu u lečenju bolesnog stanja i kondicije |
| CN114650824A (zh) * | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
-
2021
- 2021-10-29 US US18/032,876 patent/US20230398137A1/en active Pending
- 2021-10-29 WO PCT/IB2021/060045 patent/WO2022091029A1/en not_active Ceased
- 2021-10-29 TW TW110140219A patent/TW202233195A/zh unknown
- 2021-10-29 JP JP2023526258A patent/JP2023549703A/ja active Pending
- 2021-10-29 EP EP21885493.3A patent/EP4236957A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190381045A1 (en) | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease | |
| JP7069253B2 (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| TWI298255B (en) | Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder | |
| JP4664505B2 (ja) | ビュープロピオン代謝物質ならびにその合成方法および使用 | |
| EP3092231B1 (en) | Sgc stimulators | |
| US10647679B2 (en) | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto | |
| JP2002536410A (ja) | 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用 | |
| JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
| JP2023549703A5 (https=) | ||
| CN110891942B (zh) | 噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| US20230046317A1 (en) | Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer | |
| JP2023500685A5 (https=) | ||
| US20240277722A1 (en) | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent | |
| JP2023547475A5 (https=) | ||
| JP2009506043A5 (https=) | ||
| JP2015524474A (ja) | 治療レジメン | |
| JP2026510456A (ja) | Ａｍｐｋ活性化および／またはｃｈｏｐ阻害により処置できる疾患および障害の処置のためのセフィン１および関連化合物 | |
| CN101128418A (zh) | 4-羟基异亮氨酸的非对映异构体及其用途 | |
| JP2023509186A5 (https=) | ||
| US20070010541A1 (en) | Methods for treating vascular diseases | |
| KR102947841B1 (ko) | 대사 장애 치료를 위한 벤즈이미다졸 화합물 | |
| JP2015129160A (ja) | 慢性疼痛治療剤 | |
| JP2003500353A (ja) | 処置方法 | |
| JP2024042690A (ja) | 非アルコール性脂肪性肝疾患の予防及び／又は治療薬 | |
| WO2026059930A1 (en) | Methods for the treatment of overweight |